Community-acquired pneumonia: genomics, epigenomics, transcriptomics, proteomics, and metabolomics
1Department of Medicine, University of Western Australia, Perth, Australia. grant.waterer@uwa.edu.au
Seminars in Respiratory and Critical Care Medicine
|June 22, 2012
Summary
Community-acquired pneumonia research is advancing with omics technologies like genomics. These new approaches offer insights and potential applications for this persistent health challenge.
Area of Science:
- * Multi-omics research in infectious diseases.
- * Genomics, epigenomics, transcriptomics, proteomics, and metabolomics applications.
Background:
- * Community-acquired pneumonia (CAP) presents a significant, long-standing global health burden.
- * Limited therapeutic advancements have been achieved in CAP over recent decades.
Purpose of the Study:
- * To review recent multi-omics studies relevant to pneumonia.
- * To explore applications of these technologies in pneumonia and related conditions like sepsis.
- * To highlight key findings, potential uses, and barriers in the field.
Main Methods:
- * Literature review of studies employing genomics, epigenomics, transcriptomics, proteomics, and metabolomics.
- * Analysis of research in pneumonia, sepsis, and other relevant diseases.
- * Discussion of current and future applications of omics platforms.
Main Results:
- * Emerging insights and clear application pathways are evident, particularly from genomics data.
- * Multi-omics approaches reveal new perspectives on pneumonia pathogenesis and treatment.
- * Sepsis research provides valuable context for pneumonia multi-omics studies.
Conclusions:
- * Multi-omics technologies offer promising new avenues for understanding and combating community-acquired pneumonia.
- * Further research and data generation are crucial to overcome existing barriers and realize the full potential of these platforms.
- * Integration of multi-omics data is key to advancing diagnostics and therapeutics for pneumonia.
More Related Videos
11:23Purifying the Impure: Sequencing Metagenomes and Metatranscriptomes from Complex Animal-associated Samples
Published on: December 22, 2014
10:18A Fast and Reliable Pipeline for Bacterial Transcriptome Analysis Case study: Serine-dependent Gene Regulation in Streptococcus pneumoniae
Published on: April 25, 2015
Related Concept Videos
02:02Genomics
Genomics is the science of genomes: it is the study of all the genetic material of an organism. In humans, the genome consists of information carried in 23 pairs of chromosomes in the nucleus, as well as mitochondrial DNA. In genomics, both coding and non-coding DNA is sequenced and analyzed. Genomics allows a better understanding of all living things, their evolution, and their diversity. It has a myriad of uses: for example, to build phylogenetic trees, to improve productivity and...
01:33Proteomics
A proteome is the entire set of proteins that a cell type produces. We can study proteomes using the knowledge of genomes because genes code for mRNAs, and the mRNAs encode proteins. Although mRNA analysis is a step in the right direction, not all mRNAs are translated into proteins.
Proteomics is the study of proteomes' function. It involves the large-scale systematic study of the proteome to denote the protein complement expressed by a genome. Scientist Mark Wilkins coined the term proteomics...
Proteomics is the study of proteomes' function. It involves the large-scale systematic study of the proteome to denote the protein complement expressed by a genome. Scientist Mark Wilkins coined the term proteomics...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:29Pneumonia I: Introduction
Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...
01:30Pneumonia I: Introduction
Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
01:14Atypical Pneumonia
Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...